Skip to main content

Table 3 Genotype frequencies: MTHFR A1298C

From: A retrospective comparative exploratory study on two Methylentetrahydrofolate Reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients

        MTHFR A1298C    p
     AA   AC    CC  
All patients   244 (42.9%) 268 (47.1%) 54 (9.5%)  
Status Alive 152 (45.1%) 149 (44.2%) 36 (10.7%) 0.162
  Dead 92 (40.2%) 119 (52.0%) 18 (7.9%)  
Sex Male 184 (43.0%) 204 (47.1%) 40 (9.3%) 0.945
  Female 60 (43.5%) 64 (46.4%) 14 (10.1%)  
Localization AEG 152 (43.7%) 164 (47.1%) 32 (9.2%) 0.793
UICC 7th edtition Gastric cancer 87 (41.0%) 103 (48.6%) 22 (10.4%)  
Localization AEG I 60 (42.6%) 68 (48.2%) 13 (9.2%) 0.968
UICC 6th edition AEG II/III + GC 184 (43.3%) 200 (47.1%) 41 (9.6%)  
Laurén Intestinal 140 (44.0%) 150 (47.2%) 28 (8.8%) 0.835
  Non-intestinal 100 (42.9%) 109 (46.8%) 24 (10.3%)  
Grading Low grade 70 (42.4%) 77 (46.7%) 18 (10.9%) 0.76
  High grade 172 (43.8%) 186 (47.3%) 35 (8.9%)  
pT pT0 16 (42.1%) 18 (47.4%) 4 (10.5%) 0.701
  pT1 17 (33.3%) 28 (54.9%) 6 (11.8%)  
  pT2 119 (43.3%) 125 (45.5%) 31 (11.3%)  
  pT3 83 (45.4%) 88 (48.1%) 12 (6.6%)  
  pT4 9 (47.4%) 9 (47.4%) 1 (5.3%)  
pN pN0 98 (40.7%) 118 (49.0%) 25 (10.4%) 0.654
  pN1 97 (48.5%) 84 (42.0%) 19 (9.5%)  
  pN2 30 (41.1%) 37 (50.7%) 6 (8.2%)  
  pN3 9 (32.1%) 16 (57.1%) 3 (10.7%)  
  pNx 10 (41.7%) 13 (54.2%) 1 (4.2%)  
pM pM0 226 (43.3%) 244 (46.7%) 52 (10.0%) 0.402
  pM1 18 (40.9%) 24 (54.5%) 2 (4.5%)  
R R0 199 (42.0%) 226 (47.7%) 49 (10.3%) 0.239
  R1/R2 45 (48.9%) 42 (45.7%) 5 (5.4%)  
Neoadjuvant chemotherapy Yes 156 (42.6%) 179 (48.9%) 31 (8.5%) 0.4
  No 88 (44.0%) 89 (44.5%) 23 (11.5%)  
Clinical response Responder 46 (43.8%) 49 (46.7%) 10 (9.5%) 0.812
  Nonresponder 109 (41.9%) 130 (50.0%) 21 (8.1%)  
TRG 1a,1b 41 (39.4%) 55 (52.9%) 8 (7.7%) 0.628
  2,3 114 (43.8%) 123 (47.3%) 23 (8.8%)  
  1. AEG = adenocarcinoma of the esophagogastric junction, GC = gastric cancer, TRG = tumor regression grade.